Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
Business Wire•12/08/2026•07:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.